Event Calendar
Prev MonthPrev Month Next MonthNext Month
New Treatments for Atopic Dermatitis in Infants and Children
Wednesday, September 30, 2020, 1:30 PM - 3:00 PM CDT
Category: IEC Events (for everyone)



September 30, 2020 | 1:30 pm CDT | 2:30 pm EDT | 7:30 pm BST | 8:30 pm CEST

View ON-Demand Webcast


Welcome and Program Overview
Emma Guttman, IEC President, New York, NY, USA

Overview of Pediatric AD
Antonio Torrelo, Madrid, Spain

Mechanisms for Prevention of AD
Michael Cork, Sheffield, UK

Topical Therapies
Melinda Gooderham, Peterborough, ON, Canada

Systemic Therapies
Amy Paller, Past IEC President, Chicago, IL, USA

Q&A and Panel Discussion 

This program will be recorded for future viewing.




Emma Guttman, MD PhD 
Emma Guttman, MD PhD, is the Sol and Clara Kest professor of dermatology, vice chair for research at the Department of Dermatology, and director of both the Center for Excellence in Eczema and the Laboratory of Inflammatory Skin Diseases at the Icahn School of Medicine at Mount Sinai Medical Center, New York.

Guttman’s major focus is atopic dermatitis (AD). She has:

  • made paradigm-shifting discoveries on the immunologic basis of AD in humans, enriching the understanding of its pathophysiology and opening the door to new therapeutics 
  • developed comprehensive molecular maps of AD, defining skin differentiation and immune-circuits characterizing this disease
  • established the reversibility of the AD phenotype 
  • defined a series of biomarkers that are now accelerating testing of novel pathway-specific drugs for AD.

She earned her doctor of medicine degree from Sackler in Tel-Aviv, Israel, and a doctor of philosophy degree from Bar-Ilan University in Israel. After receiving her board certification in dermatology in Israel, Guttman moved to the United States to pursue a postdoctoral fellowship at The Rockefeller University in New York, NY, and a second dermatology residency at Weill Cornell Medicine in New York, NY.

In addition to serving as president of the International Eczema Council (IEC), Guttman was elected to the American Society for Clinical Investigation (ASCI) and the American Academy of Dermatology (AAD). Among other honors, she received the AAD Young Investigator Award in 2011.


Antonio Torrelo, MD

Since 2007 Dr. Torrelo has been the Head of Department of Dermatology, Hospital Infantil Niño Jesús. Prior he was a consultant in Dermatology, Hospital Infantil Niño Jesús, from 1992-2027.

He has authored and co-authored 270 scientific articles in PubMed and is the Senior editor of the 5th edition of Schachner & Hansen’s Pediatric Dermatology. He is also the Associate Editor, Pediatric Dermatology. Dr.Torrelo additionally serves as the President of the European Society for Pediatric Dermatology and has previously served as the President of the Grupo Español de Dermatología Pediátrica (2001-2004) and the International Society of Pediatric Dermatology (2013-2017).

Dr. Torrelo received his degree in medicine from the University of Modena, completed his residency in Dermatology at Hospital Ramón y Cajal, Madrid. He earned his doctoral degree from the Universidad Alcalá de Henares, Madrid.

Michael J. Cork, BSc, MB, PhD, FRCP

Professor Michael J. Cork is head of Sheffield Dermatology Research; in the Dept. of Infection, Immunity & Cardiovascular Disease; Faculty of Medicine, Dentistry & Health; at The University of Sheffield, UK. He is a Consultant Dermatologist to Sheffield Children’s Hospital (SCH) NHS Trust and to Sheffield Teaching Hospitals (STH) NHS Trust.

He specialises in treating children and adults with the most severe atopic dermatitis and sees patients from anywhere in the UK. At Sheffield Children’s Hospital he leads an integrated atopic dermatitis – allergy – psychiatry service, designed to manage the most complex patients. He leads clinical trials of new treatments for atopic dermatitis at the Clinical Research Facilities at SCH for children and at STH for adults. He is Chief Investigator, in the UK, for many of the trials for new biologics, small molecules and topicals for atopic dermatitis.

With Dr. Simon Danby, they have created a dedicated clinical research facility for skin barrier, biomarker research. Their Skin Barrier Team have developed a research facility that has developed a unique combination of techniques to assess how topical wash products, emollients and topical/systemic pharmaceutical agents affect the integrity of the skin barrier and inflammation in normal and AD skin. These biomarkers are used to assess the safety and efficacy of treatments for atopic dermatitis. These atopic dermatitis biomarkers are also being used in experimental medicine clinical trials to stratify patients according to clinical response and safety parameters. This information can be used to determine how long a treatment should be used for, the optimum dose, the effect on some comorbidities and inform health economic evaluations

Our research group also has a special interest in the prevention of atopic dermatitis. This involves both mechanistic studies and large collaborative clinical trials. We investigate how the environment of a baby interacts with their skin to induce the development of atopic dermatitis. A major focus is on how topical wash products, emollients, oils, and water itself, affect the skin barrier and how this leads to the development of atopic dermatitis. This then informs the design of combinations of topical products that will have the optimum effect on the development and maintenance of the skin barrier.


Melinda Gooderham, MD FRCPC
Dr. Gooderham is a dermatologist and medical director at the SKiN Centre for Dermatology in Peterborough, ON, Canada; an investigator with Probity Medical Research; an assistant professor at Queens University; and a consultant physician at the Peterborough Regional Health Centre. A fellow of the Royal College of Physicians and Surgeons of Canada, she is actively involved in teaching medical students, residents, nurse practitioners, and physicians with both didactic and clinical hands-on teaching. She practices with a focus on psoriasis, atopic dermatitis, skin cancer, and clinical research, and she contributes to several peer-reviewed dermatology publications as an author and reviewer.

Dr. Gooderham obtained a bachelor of science degree in 1992 from Queens University in Kingston, Ontario; a master of science in 1995 from the University of Guelph; and a medical degree from the University of Western Ontario in 1999. She completed her dermatology residency at the University of Toronto in 2004.


Amy Paller, MD MS
Amy Paller is the Walter J. Hamlin Professor and Chair of Dermatology, professor of pediatrics, and principal investigator of the NIH-funded Skin Disease Research Center at Northwestern University Feinberg School of Medicine. She directs the Pediatric Dermatology Clinical Trials Unit at Lurie Children’s Hospital of Chicago and has been the lead investigator on landmark trials involving inflammatory skin disorders. Now, she is focused on biomarker discovery for pediatric skin disease and developing patient-reported outcomes tools.

An author of more than 500 publications, Dr. Paller is an NIH-funded investigator whose laboratory focuses on nanotechnology for therapeutic delivery, diabetic wound healing, and cutaneous innervation.

She was the inaugural IEC president and has been president of the Society for Pediatric Dermatology, Society for Investigative Dermatology, Women’s Dermatologic Society, and now International Society for Pediatric Dermatology. She was also the inaugural co-chair of the Pediatric Dermatology Research Alliance and has served on the Board of Directors of the American Academy of Dermatology, Society for Investigative Dermatology, Society for Pediatric Dermatology, Women’s Dermatologic Society, American Board of Dermatology, and American Dermatological Association.

She co-authors Hurwitz Clinical Pediatric Dermatology and has edited the Journal of Investigative Dermatology, among other journals.